← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

Traditional approvalTraditional conversionUrothelial carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with locally advanced or metastatic urothelial carcinoma who are ineligible for any platinum-containing chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The traditional action narrowed the earlier indication to patients who cannot receive any platinum regimen.

What research teams should watch

Record platinum eligibility by agent rather than equating cisplatin ineligibility with ineligibility for all platinum chemotherapy.

PRIMARY RECORDS

Sources